Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells 1,998 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 1,998 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $85,554.36. Following the completion of the sale, the chief operating officer now directly owns 27,015 shares of the company’s stock, valued at approximately $1,156,782.30. This trade represents a 6.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Mirum Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ MIRM traded down $0.06 during trading on Wednesday, hitting $42.00. 305,985 shares of the company were exchanged, compared to its average volume of 405,737. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $48.89. The company has a fifty day moving average price of $42.80 and a 200-day moving average price of $40.60. The firm has a market capitalization of $2.02 billion, a PE ratio of -20.79 and a beta of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business’s revenue for the quarter was up 89.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.57) EPS. As a group, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.46 EPS for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lord Abbett & CO. LLC purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $28,913,000. Loomis Sayles & Co. L P acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $19,473,000. Clearbridge Investments LLC boosted its position in shares of Mirum Pharmaceuticals by 165.5% during the 2nd quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock worth $23,931,000 after purchasing an additional 436,349 shares during the period. State Street Corp increased its holdings in Mirum Pharmaceuticals by 19.9% in the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after purchasing an additional 297,511 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in Mirum Pharmaceuticals in the third quarter valued at approximately $10,136,000.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup raised their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Finally, Leerink Partners raised their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.